



NATIONAL
QUALITY FORUM

Opioid and Opioid Use Disorder Technical Expert Panel

CSAC Informational Update

April 23, 2019


Project Staff

- Michael Abrams, MPH, PhD, Senior Director
- Samuel Stolpe, PharmD, MPH, Senior Director
- Poonam Bal, MHSA, Senior Project Manager
- Kay Woods, MPH, MA, PMP, Project Manager
- Vaishnavi Kosuri MPH, Project Analyst
- Wunmi Isijola, MPH, Senior Managing Director

Objectives


- Provide an overview of NQF's Opioid and Opioid Use Disorder Technical Expert Panel (TEP)
- Summarize the work completed and discuss the direction of the project

The problem...



Source: Higham et al., "The Fentanyl Failure," Wash. Post, March 13, 2019

A complex problem, thus ripe for measurement...



Case and Deaton, *BPEA*, 2017; Dasgupta et al., *AJPH*, 2018; Pitt et al., *AJPH*, 2018; Chen et al., *JAMA*, 2019

Project Objectives

- NQF has convened a panel of experts that will
 - *review opioid-related quality measures and concepts*
 - » Peer-reviewed and grey literature
 - » Existing measure sets
 - » State-based laws
 - » Key stakeholders
 - *develop a set measurement priorities moving forward*
 - » For federal programs
 - » At large



Committee Composition

- Pain or substance use disorders treatment experience/expertise

AND

- Specific knowledge in one or more of the following
 - *Medicare/Medicaid/private payer*
 - *Rural health*
 - *Primary care (internal medicine, pediatrics, OB/GYN)*
 - *Specialty care (emergency, surgery)*
 - *Pharmaceutical services or drug development*
 - *Measure development*

Next Steps

Timeline	
Web Meeting 1	April 24, 2019
Web Meeting 2	May 13, 2019
Web Meeting 3	June 4, 2019
Web Meeting 4	August 13, 2019
Final Environmental Scan	September 6, 2019
Web Meeting 5	September 16, 2019
Web Meeting 6	October 10, 2019
30 Day Comment Period	December 6, 2019 – January 6, 2020
Web Meeting 7	January 21, 2020
Final Report	February 6, 2020

Discussion Questions

- Are there any resources that the CSAC would recommend that the team explore during our environmental scan?
- Are there any areas of focus the team should consider for the key informant interviews?

Thank you, questions/comments?

- Email: opioid@qualityforum.org
- Phone: 202-783-1300
- Project page
[https://www.qualityforum.org/Opioid and Opioid Use Disorder TEP.aspx](https://www.qualityforum.org/Opioid_and_Opioid_Use_Disorder_TEP.aspx)
- SharePoint page
<http://share.qualityforum.org/Projects/Opioid%20TEP/SitePages/Home.aspx>